instructiors): The broad objective of the Administrative Core is to provide multiple levels of program management support to the project and core investigators. Dr. Segal, as program director, will be responsible for all aspects of program management. To facilitate communication, coordination and planning among the projects and the INP Core, Dr. Segal will be assisted by a scientific program coordinator. Dr. Segal will also be aided by the Cancer Biology Business Office to assist her in the fiscal management of the award. The Administrative Core has three specific aims:
Aim one is to provide effective communication, coordination and planning for the program. Dr. Segal and the scientific program coordinator will schedule and facilitate monthly research -in- progress meetings for project and core investigators. The internal advisory board will be invited to this meeting on a semi-annual basis, and the external advisor will be invited to attend yearly, to provide their fresh perspectives and guidance. Following these advisory meetings, Dr. Segal and the program coordinator will synthesize the evaluations and recommendations from the advisory board and distribute them to all project and core investigators.
Aim two is to assist the Dr. Segal with fiscal management of the award. This includes processing award notices from the NIH, managing project budgets, and assisting in the preparation of annual progress reports to the NIH. Our Business Office is staffed with grants management specialists who concentrate on either pre-award or post-award aspects of research awards.
Aim three is to provide clerical support to Dr. Segal for tracking annual renewals of animal and human protocols, manuscript preparation, traveling and scheduling as it pertains to the program.
|Ni, Jing; Xie, Shaozhen; Ramkissoon, Shakti H et al. (2017) Tyrosine receptor kinase B is a drug target in astrocytomas. Neuro Oncol 19:22-30|
|Zhang, Jing; Gao, Xueliang; Schmit, Fabienne et al. (2017) CRKL Mediates p110?-Dependent PI3K Signaling in PTEN-Deficient Cancer Cells. Cell Rep 20:549-557|
|Sun, Yu; Alberta, John A; Pilarz, Catherine et al. (2017) A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. Neuro Oncol 19:774-785|
|Zhou, Jing; Tien, An-Chi; Alberta, John A et al. (2017) A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2. Cell Rep 18:3167-3177|
|Zhao, Xuesong; Pak, Ekaterina; Ornell, Kimberly J et al. (2017) A Transposon Screen Identifies Loss of Primary Cilia as a Mechanism of Resistance to SMO Inhibitors. Cancer Discov 7:1436-1449|
|Ilic, Nina; Birsoy, K?vanç; Aguirre, Andrew J et al. (2017) PIK3CA mutant tumors depend on oxoglutarate dehydrogenase. Proc Natl Acad Sci U S A 114:E3434-E3443|
|Pak, Ekaterina; Segal, Rosalind A (2016) Hedgehog Signal Transduction: Key Players, Oncogenic Drivers, and Cancer Therapy. Dev Cell 38:333-44|
|Stevens, Mark M; Maire, Cecile L; Chou, Nigel et al. (2016) Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. Nat Biotechnol 34:1161-1167|
|Ni, Jing; Ramkissoon, Shakti H; Xie, Shaozhen et al. (2016) Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med 22:723-6|
|Edwards, Amanda L; Meijer, Dimphna H; Guerra, Rachel M et al. (2016) Challenges in Targeting a Basic Helix-Loop-Helix Transcription Factor with Hydrocarbon-Stapled Peptides. ACS Chem Biol 11:3146-3153|
Showing the most recent 10 out of 57 publications